Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making

Authors

Nathanael Sanchez, Wayne State UniversityFollow

Abstract

A critical appraisal and clinical application of Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med. Sep 1 2016;194(5):559-567. doi: 10.1164/rccm.201607-1349OC.

DOI

10.22237/crp/1549411200

Recommended Citation

SANCHEZ N. Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making. Clin. Res. Prac. 2019 Feb 6;5(1):eP1628. doi: 10.22237/crp/1549411200